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Abstract
Background: Azithromycin reduces the severity of illness in patients with inflammatory lung
disease such as cystic fibrosis and diffuse panbronchiolitis. Bronchopulmonary dysplasia (BPD) is a
pulmonary disorder which causes significant morbidity and mortality in premature infants. BPD is
pathologically characterized by inflammation, fibrosis and impaired alveolar development. The
purpose of this study was to obtain pilot data on the effectiveness and safety of prophylactic
azithromycin in reducing the incidence and severity of BPD in an extremely low birth weight (≤
1000 grams) population.
Methods: Infants ≤ 1000 g birth weight admitted to the University of Kentucky Neonatal Intensive
Care Unit (level III, regional referral center) from 9/1/02-6/30/03 were eligible for this pilot study.
The pilot study was double-blinded, randomized, and placebo-controlled. Infants were randomized
to treatment or placebo within 12 hours of beginning mechanical ventilation (IMV) and within 72
hours of birth. The treatment group received azithromycin 10 mg/kg/day for 7 days followed by 5
mg/kg/day for the duration of the study. Azithromycin or placebo was continued until the infant no
longer required IMV or supplemental oxygen, to a maximum of 6 weeks. Primary endpoints were
incidence of BPD as defined by oxygen requirement at 36 weeks gestation, post-natal steroid use,
days of IMV, and mortality. Data was analyzed by intention to treat using Chi-square and ANOVA.
Results: A total of 43 extremely premature infants were enrolled in this pilot study. Mean
gestational age and birth weight were similar between groups. Mortality, incidence of BPD, days of
IMV, and other morbidities were not significantly different between groups. Post-natal steroid use
was significantly less in the treatment group [31% (6/19)] vs. placebo group [62% (10/16)] (p =
0.05). Duration of mechanical ventilation was significantly less in treatment survivors, with a median
of 13 days (1–47 days) vs. 35 days (1–112 days)(p = 0.02).
Conclusion: Our study suggests that azithromycin prophylaxis in extremely low birth weight
infants may effectively reduce post-natal steroid use for infants. Further studies are needed to
assess the effects of azithromycin on the incidence of BPD and possible less common side effects,
before any recommendations regarding routine clinical use can be made.
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Background
Bronchopulmonary dysplasia (BPD) is a common disor-
der among extremely low birth weight infants, with an
incidence ranging from 30% to 75% in infants weighing
less than a 1000 grams at birth[1]. It is a major cause of
morbidity and mortality in the preterm infants and has
been associated with long-term pulmonary function
abnormalities[2], prolonged oxygen therapy, reactive air-
way disease, and respiratory infections frequently requir-
ing rehospitalization. All of these pose a significant
financial burden on the healthcare system[3].
Development of BPD is associated with antenatal and
postnatal factors that lead to an arrest of lung develop-
ment [4-6]. Antenatally, maternal chorioamnionitis is
associated with later development of BPD[7], with Urea-
plasma urealyticum being the most common association
with chorioamnionitis at less than 30 weeks gestational
age[8]. The role of Ureaplasma urealyticum antenatally
and postnatally is yet to be determined. There is evidence
that Ureaplasma urealyticum causes an inflammatory
response[9,10], but evidence is conflicting regarding its
role in the pathogenesis of BPD [11-14]. Postnatal insults
include oxygen toxicity, barotrauma and volutrauma from
mechanical ventilation, and sepsis. These additional
insults lead to activation of the inflammatory cascade and
significantly increase the risk of BPD.
The prevention and treatment of BPD to date has prima-
rily focused on the use of dexamethasone because of its
potent anti-inflammatory effect. The use of dexametha-
sone, however, has not been without significant side-
effects. Studies evaluating the efficacy of early postnatal
dexamethasone and hydrocortisone were terminated early
secondary to increased complications, including high
rates of gastrointestinal perforation with both medica-
tions[15,16]. Yeh, et al, reported that infants treated post-
natally with dexamethasone had significant motor and
cognitive impairment when compared with matched con-
trols. Schreiber et al used nitric oxide as an anti-inflamma-
tory agent. They demonstrated a 14% decrease in the
incidence of BPD in infants surviving to discharge without
evidence of adverse outcome[17]. Although nitric oxide
appears to be marginally effective in prevention of BPD,
larger clinical trials by Kinsella et al have demonstrated a
possible neuroprotective role[18]. Other therapies that
have been utilized for the treatment of BPD include vita-
min A, which reduces the incidence of BPD by 5–7%[19].
Macrolide antibiotics have anti-inflammatory properties
and are thought to inhibit inflammation at multiple
points in the inflammatory cascade. Anti-inflammatory
actions include inhibiting pro-inflammatory cytokines,
inhibiting crucial inflammatory transcription factors, and
acting as free radical scavengers. Macrolides are also
known to directly inhibit neutrophil chemotaxis and
inhibit superoxide generation by activated neutrophils
[20-24]. These actions at multiple points in the inflamma-
tory cascade make macrolide antibiotics potentially useful
in any chronic inflammatory condition.
Macrolides have been used with success in the treatment
of other inflammatory pulmonary diseases, including dif-
fuse panbronchiolitis, cystic fibrosis, and post-transplant
bronchiolitis obliterans [25-29]. Macrolides are known to
accumulate intracellularly and inhibit neutrophil migra-
tion to sites of inflammation[24]. They are also known to
inhibit various pro-inflammatory cytokines such as IL-1,
IL-6, and TNF-α, as well as NF-κB, a primary transcription
factor in the inflammatory cascade[20-24,30]. Newer gen-
eration macrolides, such as azithromycin and clarithro-
mycin, are characterized by fewer side-effects and
increased anti-inflammatory properties when compared
to erythromycin [31-34]. Additionally, azithromycin has
increased antimicrobial activity against Ureaplasma urea-
lyticum when compared to erythromycin[35,36].
The inflammatory nature of BPD is clearly established,
but a safe and affordable therapy that will decrease its
severity and incidence is lacking. Azithromycin, a mac-
rolide antibiotic, has potent anti-inflammatory properties
and an excellent side effect profile, but it has not been
studied in premature infants. We performed a pilot study
to evaluate the efficacy and safety of azithromycin in the
prevention of BPD. Our hypothesis is that prophylaxis
with azithromycin is both safe and effective at reducing
the incidence and severity of BPD in the extremely pre-
term infant.
Methods
The pilot study was double blinded, placebo controlled,
randomized, and approved by the Institutional Review
Board at the University of Kentucky. Infants admitted to
the University of Kentucky Neonatal Intensive Care Unit
from September 2002 to June 2003 were eligible for
enrollment into our study. Enrollment criteria included
birth weight ≤ 1000 grams, intermittent mechanical ven-
tilation ≤ 12 hrs duration, and ≤ 72 hours of age.
Informed consent was obtained when the infant met
enrollment criteria.
Exclusion criteria included lack of parental informed con-
sent, confirmed sepsis by blood culture drawn at admis-
sion, multiple congenital anomalies or known
syndromes, and intrauterine growth retardation with
birth weight less than tenth percentile for gestational age.
Infants who did not receive mechanical ventilation were
not eligible for the study.
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The University of Kentucky Investigational Drug Service
performed randomization in blocks of six. Upon enroll-
ment each infant was randomized to receive azithromycin
or placebo for a total of 6 weeks. The treatment group
received 10 mg/kg of azithromycin daily for 7 days, fol-
lowed by 5 mg/kg of azithromycin for an additional 5
weeks. This dosing regimen was selected based on prior
studies in cystic fibrosis using a 3 month course of azithro-
mycin [26], combined with the nature of BPD being a sus-
tained inflammatory disease. Study drug and placebo
were initially administered intravenously, and switched to
the enteral route once the infant reached full enteral feeds.
The placebo group received an equivalent volume of nor-
mal saline daily for 6 weeks. The study drug or placebo
was discontinued in the event that infants weaned from
mechanical ventilation and supplemental oxygen prior to
completion of 6 weeks.
Tracheal aspirates were collected at enrollment for Urea-
plasma urealyticum and Mycoplasma culture. Cultures
were collected using sterile technique with 0.9% saline
lavage. Samples were immediately placed on ice and proc-
essed in the clinical laboratory by inoculating REMEL's
Micro Test™, a selective transport media formulated for
Ureaplasma and Mycoplasma species. Subsequently they
were transported frozen to ARUP laboratories in Salt Lake
City, Utah for Ureaplasma and Mycoplasma species cul-
ture. If an infants respiratory culture was positive for
either Ureaplasma or Mycoplasma, the infant was
removed from the study secondary to uncertainty regard-
ing the role of these organisms in the pathogenesis of
BPD. The selected macrolide and duration of therapy for
infants with positive cultures for Ureaplasma or Myco-
plasma was at the discretion of the attending neonatolo-
gist caring for the infant.
Baseline tracheal fluid aspirates for cytokine determina-
tion were collected at enrollment, on day 3 of treatment,
and weekly thereafter while intubated and on study. Ster-
ile saline (0.9%) was instilled into the endotracheal tube
in four aliquots of 0.5 cc. Fluid was collected into a sterile
trap by tracheal suctioning after installation of each aliq-
uot. After the retrieval of the fourth aliquot of saline the
catheter was cleared with 0.5 cc of normal saline. Aspirates
were transported on ice and processed immediately. The
aspirate was spun for 10 minutes at 1000 g and the super-
natant frozen at -70°C. Samples were analyzed in tripli-
cate by ELISA for IL-8 (Quantikine® Human IL-8
Immunoassay, Minneapolis, MN) according to the manu-
facturer's protocol, and the reported value of each sample
averaged.
Clinical data were collected at enrollment, on days 3, 5, 7,
then weekly for the duration of the study, and at dis-
charge. Data collected included demographic informa-
tion, mechanical ventilation parameters, blood gas
values, mean arterial blood pressure, doses and type of
surfactant therapy, total fluids, episodes of bacterial and
fungal sepsis, episodes of feeding intolerance (defined as
feeds being held for more than 24 hours once initiated),
time to full feedings (defined as when the total parental
nutrition was discontinued), intraventricular hemorrhage
(IVH) diagnosed by head ultrasonography (HUS), periv-
entricular leukomalacia (PVL) seen on HUS, episodes of
necrotizing enterocolitis (NEC) Bell's grade II or higher,
hearing screen results, hepatic function test (AST), bron-
chodilator therapy, diuretic therapy, caffeine therapy, and
hospital days.
Primary outcomes were incidence of BPD defined as sup-
plemental oxygen at 36 weeks post-menstrual age, dura-
tion of mechanical ventilation, post-natal steroid use, and
mortality. Post-natal steroids were administered at the dis-
cretion of the attending neonatologist.
This pilot study was terminated after 9 months of enroll-
ment to perform data analysis for data safety monitoring,
and estimation of sample size. The end-points were the
incidence and severity of BPD, with the severity being
measured by the duration of mechanical ventilation and
post-natal steroid use.
All infants who survived to discharge were scheduled for
follow-up at 12 and 24 months corrected age in our NICU
graduate clinic for history, physical examination and
developmental evaluation. Their neurodevelopmental
assessment included Bayley Scales of Infant Development
II (BSID-II) and Pre-school Language Scale-4 (PLS-4).
Assessments were performed by certified personnel who
were blinded to the infants randomization.
Categorical data was analyzed using Chi-square or Fisher's
exact test where appropriate, and continuous data was
analyzed using ANOVA or median test. JMP® (Cary, NC)
software was used for all data analysis.
Results
From September 2002 to June 2003 there were a total of
49 infants admitted to the University of Kentucky Neona-
tal Intensive Care Unit who met the eligibility criteria for
our study (Figure 1). These infants were born to a total of
41 mothers, of which 36 signed informed consent for
their infant to be enrolled in the study. Of the 49 eligible
infants, 43 were enrolled (30 singletons, 5 sets of twins,
and 1 set of triplets). Reasons for not enrolling the infants
included not being able to meet the time criteria (3 cases),
the parent not being available for consent (1 case), and
the parents refusing participation (1 case). Eight infants
had respiratory cultures that were positive for myco-
plasma or ureaplasma at the time of enrollment, and were
Respiratory Research 2007, 8:41 http://respiratory-research.com/content/8/1/41
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removed from the data analysis. Table 1 compares the
study and control groups according to demographic and
clinical information at enrollment. Groups were similar as
to birth weight, gestational age, gender, cesarean section,
and use of antenatal steroids.
The primary outcomes analysis of all respiratory culture
negative infants showed equivalent mortality 26.3% (5 of
19) for the azithromycin group as compared to 25% (4 of
16) for the placebo group (p = 0.9). Incidence of BPD was
64.3% (9 of 14) for the azithromycin group vs. 83.3% (10
of 12) for the placebo group (p = 0.26). Median duration
of mechanical ventilation was 10 days (range 1–145) for
the azithromycin group vs. 16 days (range 1–112) for the
placebo group (p = 0.4). Post-natal steroid use to facilitate
weaning from mechanical ventilation was significantly
less in the azithromycin group with 31.5% (6 of 19) vs.
62.5% (10 of 16) in the placebo group (p = 0.05) receiv-
ing steroids (Table 2).
Secondary outcomes and data safety monitoring showed
no difference in the following: IVH Grade III or IV, PVL,
abnormal liver function test, peak bilirubin, days to full
feedings, feeding intolerance, necrotizing enterocolitis
(NEC), abnormal hearing screen, bacterial or fungal infec-
tions, antibiotic usage, methylxanthine therapy, incidence
of PDA, indocin therapy, PDA ligation, days of CPAP, hos-
pital days, oxygen concentration at 36 weeks PCA, diuretic
or bronchodilator use (Table 2).
Analysis of data from survivors showed a significant
reduction in days of mechanical ventilation with a
median of 13 days (range 1–47) for the azithromycin
group vs. median 35 days (range 1–112) for the placebo
group (p = 0.02) (Figure 2). Post-natal steroid use contin-
ued to be significantly less in the azithromycin group,
with 3 of 16 vs. 8 of 12 in the placebo group receiving ster-
oids (p = 0.01) (Table 3).
Table 1: Base-line characteristics for all patients enrolled in the study
Characteristic Azithromycin Group (n = 19) Placebo Group (n = 16) p-value
Birth weight-g 762 ± 94 736 ± 103 NS
Gestational age-wk 25.6 ± 1.5 25.3 ± 1.0 NS
Male sex-no. (%) 7 (36.8) 8 (50) NS
Mother's racial group-no. (%)
Black 1 (4.5) 0 NS
White 17 (89.5) 16 (100)
Other 1 (4.5) 0
Born at study hospital-no. (%) 17 (89.5) 13 (81.3) NS
Antenatal Steroids-no. (%) 15 (78.9) 12 (75) NS
Cesarean section-no. (%) 17 (89.5) 14 (87.5) NS
Apgar score at 1 minute
Median 5 4 NS
Interquartile range 2–6 1–7
Apgar score at 5 minute
Median 7 7 NS
Interquartile range 6–8 5–8
Initial mean airway pressure 6.8 ± 1.3 6.6 ± 0.9 NS
Surfactant-no. of doses 1.4 ± 0.7 1.8 ± 0.7 NS
Clinical history of chorioamnionitis-no. (%) 1 (5.2) 1 (6.2) NS
All data analysis was performed using ANOVA (mean ± sd), except for apgar scores, which was analyzed using median test. All p-values are 
recorded as NS (not significant) if > 0.05.
Flow diagram of patientsigure 1
Flow diagram of patients. Demonstrates the flow of 
patients for the pilot study.
8 infants were removed the 
pilot study because of a 
positive culture for 
ureaplasma or mycoplasma 
(3 in the azithromycin group 
and 5 in the placebo group
Screened all infants 
admitted to the NICU 
between September 2002 
thru June 2003 (total = 580 
admissions) 
Azithromycin Group
(n=19)
Placebo Group
(n=16)
Informed consent obtained (43 
infants to 36 moms). 
Eligible infants 
(49 infants born to 41 moms). 
Investigational Pharmacy 
Randomized 
30 singletons, 5 sets of twins, and 
1 set of triplets
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Secondary outcomes for the survivors showed a signifi-
cant reduction in length of stay (LOS). Treatment group
LOS was 77 ± 15 days (range 47–108), vs. 101 ± 32 days
(range 49–170), for the placebo group (p = 0.04) (Table
3).
There were a total of 10 infants who did not complete the
study. Reasons for not completing the study were death (4
placebo group, 5 azithromycin group), and reversal to a
regional hospital (1 azithromycin group). Gestational age
and birth weight did not differ between groups. The
median days of survival was 4 (range 1–166) for the azi-
thromycin group vs 8 (range 1–21) for the placebo group.
Causes of death included hypoxic respiratory failure (2
placebo group, 1 azithromycin group), hyperkalemia (2
azithromycin group), fungal sepsis (1 placebo group, 1
azithromycin group), suspected sepsis (1 placebo group),
and cardiopulmonary arrest (1 placebo group). There
were no side-effects that could be attributed to the azi-
thromycin therapy during or after our study. Mean arterial
pressure, feeding intolerance, hepatic function, peak
bilirubin, episodes of apnea receiving treatment with caf-
feine, episodes of bacterial or fungal sepsis, incidence of
PDA, episodes of NEC, incidence of IVH or PVL, and
abnormal hearing screens were comparable between the
study and placebo groups.
Results of the tracheal aspirate analysis for IL-8 are shown
in figure 3. There are numerous missing values secondary
to infants not completing the study due to mortality.
Additionally, infants who received azithromycin required
mechanical ventilation for a median of 13 days, and there-
Table 2: Outcomes for all patients
Azithromycin Group
(n = 19)
Placebo Group
(n = 16)
p-value
Mortality-no. (%) 5 (26.3) 4 (25) 0.9
Incidence of BPD-no. (%) 9 (64.3) 10 (83.3) 0.26
Duration of Mechanical 
Ventilation-median (range)
10 (1–145) 16 (1–112) 0.40
Postnatal-steroid 6 (31.5) 10 (62.5) 0.05
Days of CPAP (range) 6 ± 7 6 ± 6 0.84
Grade III or IV IVH-no. (%) 5 (26) 5 (33) 0.65
PVL on HUS-no. (%) 1 (5) 3 (19) 0.20
Abnormal Transaminases (AST) 0 1 0.20
Bilirubin Peak 6.5 ± 2 6.3 ± 1.9 0.68
Days to full feeds‡ 18 ± 5 18 ± 54 0.95
Feeding intolerance*-no. (%) 5 (26) 9 (56) 0.07
Necrotizing Enterocolitis-no. (%) 0 1 (6) 0.20
Abnormal hearing screen-no. (%) 0 3 (25) 0.08
Bacterial Infection:
Blood-no. (%) 10 (52) 6 (38) 0.35
Urine-no. (%) 1 (5) 4 (25) 0.15
CSF-no. (%) 0 2 (12) 0.20
Fungal Infection:
Blood-no. (%) 3 (16) 2 (12) 0.78
Urine-no. (%) 0 2 (12) 0.20
CSF-no. (%) 1 (5) 0 1
Days of Antibiotics§ 10 ± 10 19 ± 21 0.10
Caffeine Therapy-no. (%) 13 (68) 10 (62) 0.71
PDA†-no. (%) 10 (52) 12 (75) 0.16
Courses of indomethacin 0.49
Median 1 1
Interquartile range 0–1 0–2
PDA ligated-no. (%) 3 (15) 4 (25) 0.49
Diuretics-no. (%) 6 (31) 8 (50) 0.26
Days of Diuretics 14 ± 30 21 ± 38 0.53
Bronchodilators-no. (%) 5 (26) 8 (50) 0.14
Days of Bronchodilators 10 ± 25 18 ± 24 0.34
Hospital days 67 ± 40 78 ± 50 0.47
All data analysis was performed using ANOVA (mean ± sd), except for indomethacin and days of mechanical ventilation, which was analyzed using 
median test. *Defined as feeds being held for more than 24 hours, while on study. †Confirmed by echocardiogram. ‡Defined as when TPN was 
discontinued. §Excluding azithromycin.
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fore did not have tracheal aspirates collected after extuba-
tion. The IL-8 results are not statistically different between
groups.
Among the survivors, 32 were scheduled for developmen-
tal follow-up at 12 and 24 months corrected age, with 22
of 32 (69%) returning for follow-up. The mean corrected
age at follow-up was 16.5 ± 5.2 months for azithromycin
group and 18.3 ± 5.4 months for the placebo group. There
were no differences in the number of hospital re-admis-
sions or days on oxygen after discharge between groups,
and no infants had been diagnosed with hypertrophic
pyloric stenosis. The results of their growth parameters,
BSID-II, and PLS-4 are shown in Table 4.
Discussion
BPD is known to be an inflammatory disease of the lungs
that predominantly affects preterm infants[37,38]. Risk
factors include prematurity, maternal chorioamnionitis,
mechanical ventilation, oxygen therapy, and sepsis[6,39].
Antenatal and postnatal factors contribute to an activation
of the inflammatory cascade and subsequent develop-
ment of BPD. Tracheal aspirates from infants with BPD
have increased neutrophil counts as well as elevated pro-
inflammatory cytokines including TNF-α, IL-1, and IL-6
[40-43]. The elevated neutrophil counts are thought to
contribute to impaired lung morphogenesis by transport-
ing and releasing harmful proteases[44]. These many fac-
tors lead to an arrest of lung development which is the
hallmark of BPD[5].
Therapies to prevent and treat BPD have remained elusive.
Early post-natal steroid use is effective, but not without
significant side-effects[15]. Nitric oxide may be beneficial
as an anti-inflammatory agent, but at significant cost[17].
Vitamin A therapy is the only treatment that has been
demonstrated to be beneficial, with a 5–7% decrease in
the incidence of BPD[19]. This study presents pilot data
that strongly supports the need for additional evaluation
of azithromycin in the treatment and prevention of BPD.
The first macrolide to be used clinically for its anti-inflam-
matory properties was erythromycin, which improved
survival in diffuse panbronchiolitis from less than 50% to
about 90%[25]. In patients with cystic fibrosis azithromy-
cin has been shown to improve the forced expiratory vol-
ume in 1 second (FEV1), decrease respiratory
exacerbations requiring hospitalization, and improve
quality of life[26]. A recent pilot study showed some pos-
sible benefit of azithromycin in bronchiolitis obliterans
syndrome by improving FEV1 and quality of life in pulmo-
nary transplant patients[28]. Knowing that all of the pre-
viously mentioned lung diseases have predominant
inflammatory components, it is reasonable to evaluate the
role of macrolides in the prevention and treatment BPD.
Tracheal aspirate IL-8 valuesFigur  3
Tracheal aspirate IL-8 values. Demonstrates the tracheal 
aspirate values that were collected at enrollment into the 
study (day 0) and then study days 3, 7, 14, 21, 28, 35 and 42. 
The ❍ represents values for the control group, and the - 
represents values for the azithromycin group. There are 
numerous missing values due infants being extubated, and 
therefore not being able to collect tracheal aspirates. The p-
value is not significant between groups.
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We designed a pilot study to investigate the anti-inflam-
matory effects of azithromycin in extremely preterm
infants at high risk for BPD. Our pilot study excluded
infants who had respiratory cultures that were positive for
Ureaplasma urealyticum or Mycoplasma hominis. This
was done because of the undetermined role of these
organisms in the pathogenesis of BPD [11-14]. There is
evidence that Ureaplasma causes an inflammatory
response[9,10], but prior studies evaluating treatment of
Ureaplasma in preterm infants have not demonstrated
any benefit[45,46]. The uncertainty in this area is further
demonstrated by the recent Food and Drug Administra-
tion request for proposals titled "Effectiveness of intrave-
nous azithromycin for the prevention of
bronchopulmonary dysplasia in preterm neonates colo-
nized with Ureaplasma urealyticum".
This study had inadequate sample size to make any con-
clusions regarding its affect on the incidence of BPD and
could not assess for possible side effects that have an
exceedingly low incidence. This study was intended to
obtain pilot data for a larger trial. Potential concerns for
the use of azithromycin include late onset infections, par-
ticularly fungal sepsis, antimicrobial resistance, hepato-
toxicity, hearing impairment, and other gastrointestinal
side-effects especially with a prolonged course of therapy.
Possible association with cardiac arrhythmias has not
been identified, but would also need to be monitored. We
found that the incidence of these were similar to placebo.
Although the macrolide erythromycin has been reported
to be associated with hypertrophic pyloric stenosis[47],
this complication was not seen in our study and has not
been reported with azithromycin.
Table 3: Outcomes for survivors
Azithromycin Group
(n = 14)
Placebo Group
(n = 12)
p-value
Incidence of BPD-no. (%) 9 (64.3) 10 (83.3) 0.26
Duration of Mechanical 
Ventilation-median (range)
13 (1–47) 35 (1–112) 0.02
Postnatal-steroid 3 (18.8) 8 (66.7) 0.02
Days of CPAP (range) 8 ± 7 8 ± 6 0.98
Grade III or IV IVH-no. (%) 2 (14) 2 (16) 0.86
PVL on HUS-no. (%) 1 (7) 2 (16) 0.58
Abnormal Transaminases (AST) 0 1 (8) 0.46
Bilirubin Peak 6.9 ± 1.8 6.4 ± 2.1 0.54
Days to full feeds‡ 17 ± 5 18 ± 4 0.76
Feeding intolerance*-no. (%) 4 (29) 7 (58) 0.12
Necrotizing Enterocolitis-no. (%) 0 1 (8) 0.46
Abnormal hearing screen-no. (%) 0 3 (25) 0.08
Bacterial Infection:
Blood-no. (%) 8 (57) 5 (42) 0.43
Urine-no. (%) 0 3 (25) 0.08
CSF-no. (%) 0 2 (17) 0.20
Fungal Infection:
Blood-no. (%) 2 (14) 1 (8) 1.0
Urine-no. (%) 0 1 (8) 0.46
CSF-no. (%) 1 (7) 0 1.0
Days of Antibiotics§ 12 ± 11 24 ± 23 0.09
Caffeine Therapy-no. (%) 13 (92) 10 (83) 0.58
PDA†-no. (%) 7 (50) 9 (75.0) 0.18
Indomethacin¥
Median 1 1 0.48
Interquartile range 0–1 0–2
PDA ligated-no. (%) 3 (21) 3 (25) 0.82
Diuretics-no. (%) 5 (35) 7 (58) 0.24
Days of Diuretics 12 ± 25 28 ± 42 0.23
Bronchodilators-no. (%) 4 (28) 8 (67) 0.05
Days of Bronchodilators 7 ± 15 24 ± 25 0.04
Hospital days 77 ± 15 101 ± 32 0.02
All data analysis was performed using ANOVA (mean ± sd), except for apgar scores and days of mechanical ventilation, which analyzed using 
median test. *Defined as feeds being held for more than 24 hours, while on study. †Confirmed by echocardiogram. ‡Defined as when TPN was 
discontinued. §Excluding azithromycin. ¥Performed using wilcoxon rank sum test.
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In this pilot study we found no statistically significant
decrease in BPD, although the incidence in the azithromy-
cin-treated infants was 19% lower than in the placebo-
treated infants. Several measures of the severity of lung
disease were significantly decreased in the treated infants,
including days on mechanical ventilation and length of
stay. These data justify further study of the effects of azi-
thromycin on BPD in the extremely low birth weight
infant. Larger trials would need to monitor closely for tox-
icities associated with azithromycin, and continue to
include long-term neurodevelopmental follow-up.
Conclusion
Our pilot study showed that infants treated with azithro-
mycin prophylaxis were less likely to receive postnatal
steroids. Survivors also had shortened duration of
mechanical ventilation, and shortened hospital stay when
receiving azithromycin prophylaxis. Side effects of azi-
thromycin prophylaxis were minimal and similar to pla-
cebo. Further studies are needed before azithromycin can
be recommended for routine therapy in the treatment of
BPD.
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